Federated Hermes Inc. Has $17.06 Million Stake in ADMA Biologics Inc $ADMA

Federated Hermes Inc. trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 936,981 shares of the biotechnology company’s stock after selling 267,146 shares during the period. Federated Hermes Inc. owned 0.39% of ADMA Biologics worth $17,062,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Amundi acquired a new stake in ADMA Biologics during the 2nd quarter worth $707,000. Marshall Wace LLP bought a new position in shares of ADMA Biologics in the 2nd quarter worth $384,000. Baird Financial Group Inc. acquired a new stake in shares of ADMA Biologics during the second quarter worth $2,090,000. Kennedy Capital Management LLC grew its stake in shares of ADMA Biologics by 4.3% during the second quarter. Kennedy Capital Management LLC now owns 427,036 shares of the biotechnology company’s stock worth $7,776,000 after purchasing an additional 17,544 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

ADMA opened at $19.98 on Thursday. The stock has a market cap of $4.76 billion, a P/E ratio of 23.23 and a beta of 0.43. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The company has a fifty day simple moving average of $16.25 and a 200 day simple moving average of $17.27.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The firm had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. During the same period in the previous year, the company posted $0.15 earnings per share. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.